The primary therapeutic use of Даларгин-ДЕКО, based on its active ingredient, is applied across domains where additional symptomatic support is needed in conditions involving acute and disruptive episodes of digestive pathologies. It is used in settings marked by temporary physiological imbalance and where short-term symptomatic assistance is needed.

The treatment is commonly used for managing conditions characterized by periods of heightened symptoms and significant symptomatic burden, which include exacerbations of peptic ulcer disease (gastric and duodenal ulcers), the acute phase of pancreatitis, and supportive care for certain presentations of ulcerative colitis.

The core benefit is that the therapy supports the patient during difficult episodes by easing the overall symptom load. It is relevant for easing symptoms linked to organ-specific functional stress caused by severe inflammation, supporting the patient's stability during acute phases.

---

Quick Fact: Relief for Severe Digestive Strain

Feature	Therapeutic Role
Key Use	Managing symptoms related to inflammatory or irritative states associated with mucosal strain.
Main Support	Contributes to improved comfort during periods of heightened symptoms.
Use Context	Applied in clinical settings for acute inflammatory crises in organs like the pancreas, assisting with maintaining functional stability.

The eligibility profile for Даларгин-ДЕКО is strictly defined by official regulatory documentation, establishing absolute contraindications for several populations and clinical conditions. The medicine is approved for use exclusively in the adult population, 18 years of age and older. Use is permitted only if the patient does not present with the specific comorbidities or statuses listed below.

---

Eligibility Status	Excluded Populations
Absolute Contraindication	Children and adolescents under 18 years; pregnant and breastfeeding individuals.
Absolute Contraindication	Patients with arterial hypotension (low blood pressure) or acute infectious processes.
Absolute Contraindication	Known hypersensitivity to the active substance or any excipients.

---

Use Limitation	Regulatory Statement
Conditional Caution	Recommended for individuals performing potentially hazardous activities, such as driving or operating machinery, due to the labeled risk of reduced blood pressure.
Data Limitation	Official instructions do not specify usage guidelines or data for adults with chronic hepatic or renal impairment.

---

This profile governs who can and cannot receive the medicine based solely on regulatory assessment of population eligibility, ensuring exclusion for specific age groups, physiological states, and comorbid conditions.

Interactions with other medicines and products

The following summary reflects the official prescribing information for Даларгин-ДЕКО (Dalargin) as stated within authoritative governmental regulatory documentation. This section is strictly limited to pharmacokinetic, pharmacodynamic, or other co-administration constraints specified by regulatory bodies.

Official Interaction Profile Status

Category	Regulatory Status
Documented Drug-Drug Interactions	Not explicitly detailed in accessible official regulatory sources.
Metabolic Pathway Involvement	No specific enzyme (e.g., CYP) or transporter-mediated effects are stated in the official label.
Timing-Based Rules	No mandatory administration separation intervals or specific timing constraints are documented.
Interactions with Food, Alcohol, or Supplements	No specific restrictions or documented interactions with food, alcohol, or herbal products are included in the official label.
Contraindicated Combinations	No medicinal products are formally listed as contraindicated due to an interaction risk with Dalargin.

Connection to the Regulatory Structure

The official interaction profile for this drug is characterized by the absence of documented specific interaction warnings in publicly available regulatory prescribing information. The official label does not describe any mandatory timing rules, specific interacting agents that alter exposure, or metabolic restrictions that require dose adjustments for co-administered medicines. Consequently, the regulatory documentation for Dalargin provides no formally specified requirements or constraints related to co-administration based on interaction risk.

Даларгин-ДЕКО functions as a synthetic peptide that exerts its primary action by binding as an agonist to delta- and mu-opioid receptors located on the cell surfaces of various tissues, including the gastrointestinal tract and the nervous system. The compound mimics the effect of endogenous enkephalins, initiating intracellular signaling cascades upon receptor occupancy.

Activation of these G-protein coupled receptors (GPCRs) leads to the inhibition of adenylyl cyclase activity, which results in a reduction of intracellular cyclic AMP (cAMP) levels. This reduction modulates the activity of protein kinase A (PKA) and alters the phosphorylation state of multiple downstream targets.

At a systemic level, this mechanism promotes the alteration of local microcirculation and the modification of gastric mucosal integrity factors. Specifically, the peptide influences the release and activity of certain regulatory mediators and growth factors, contributing to the physiological modulation of tissue maintenance processes.

The use of Даларгин-ДЕКО is strictly governed by prescription, and its unique formulation as a lyophilisate (freeze-dried powder) requires it to be administered only via parenteral injection. This non-oral route ensures proper systemic delivery of the active hexapeptide, Dalargin.

Preparation and Administration

The medicine is intended for use exclusively in a clinical setting and requires mandatory steps prior to injection: The 1 mg lyophilisate must be reconstituted immediately before use by dissolving the powder in exactly 1 mL of 0.9% Sodium Chloride solution for injection. For intravenous (IV) administration, the reconstituted solution is typically diluted further in 5 to 10 mL of 0.9% Sodium Chloride solution. The official instructions strictly prohibit mixing the drug with any other solution.

Dosing and Treatment Duration

The appropriate dose and administration frequency are dependent upon the specific acute gastrointestinal condition being treated, in accordance with official prescribing information.

Indication	Single Dose Range	Frequency and Route
Peptic Ulcer Exacerbation	1 mg to 2 mg	IM (Twice Daily) or IV (Once Daily)
Acute Pancreatitis	2 mg (initial), then 5 mg	1 to 2 times daily (IV)
Acute Necrotic Pancreatitis	5 mg	3 to 4 times daily (IV)

The full course of treatment is strictly time-bound: peptic ulcer therapy lasts for 3 to 4 weeks (with a maximum cumulative dose of 50 mg), while acute pancreatitis courses range from 2 to 6 days.

Population Use Constraints

Official instructions explicitly contraindicate the use of this medicine in the pediatric population (children). No specific dose adjustments are specified in the official documentation for use in older adults or patients with existing hepatic or renal impairment.

Research evidence / Overview of studies for Даларгин-ДЕКО

The available research on Даларгин-ДЕКО primarily consists of clinical trials, comparative studies, and drug evaluations, with much of the data originating from older publications. This summary reflects what the research has explored and what findings have been described, adhering strictly to the current evidence landscape.

---

Evidence for use in Peptic Ulcer Disease (PUD)

Research was studied for conditions associated with acute or disruptive episodes in adult populations. Studies monitored outcomes such as the rate of complete ulcer healing observed via endoscopy and measured outcomes related to physical discomfort and duodenogastric reflux. Some comparative trials reported observations that regimens involving the peptide was associated with patterns of early ulcer scarring. However, one randomized study reported that a comparator medication's effect on ulcer healing differed statistically from the patterns observed with the Dalargin regimen. These findings were mixed, and the independent contribution of the peptide is not clearly separated in combination therapies.

---

Evidence for use in Chronic Pancreatitis

The compound was investigated in studies where it was applied as a component of other therapies in adult patients with Chronic Pancreatitis. Researchers monitored outcomes related to systemic or functional imbalance by tracking blood levels of certain pancreatic enzymes and hormones, as well as outcomes related to physical discomfort. The findings describe patterns observed in the studies where the combined treatment approach was associated with changes in symptoms and reported measurements related to certain pancreatic function markers. The main limitation is that comparative evidence is lacking for the peptide when used as a single agent, and the data show patterns related to a combined regimen.

---

Limitations, Study Duration, and Research Gaps

The evidence base is characterized by short observation periods; long-term effects are not fully established, and follow-up durations were limited to acute phases. Furthermore, clinical research has focused overwhelmingly on adult populations. Data for certain groups remain insufficient, including children, older adults, and pregnant women. The evidence quality varies across studies, relying on older data, which means the context of care and diagnostic techniques may differ from current standards.

Common questions about Даларгин-ДЕКО (FAQ)

---

Q: Can people with liver problems use Даларгин-ДЕКО?

Official instructions and prescribing information do not specify usage guidelines or provide specific data regarding the use of this medicine in adults who have pre-existing chronic hepatic (liver) impairment. Any medical eligibility, especially for patients with liver issues, is determined by a healthcare professional.

---

Q: Does Даларгин-ДЕКО have an impact on kidney function?

Official regulatory instructions do not specify usage guidelines or provide clinical data concerning the use of the medicine in adults with pre-existing chronic renal (kidney) impairment. The potential impact on kidney function for these patients is not addressed in the publicly available official documentation.

---

Q: Can older adults (seniors) safely use Даларгин-ДЕКО?

The official documentation does not specify high-level dose adjustments for older adults. While the drug is approved for the adult population, research data specifically focused on seniors is noted in scientific literature as being limited. The decision to use this medicine in the elderly population is made by a healthcare professional.

---

Q: Is it common to have an allergic reaction to Даларгин-ДЕКО?

Allergic reactions are listed in official regulatory summaries as a possible adverse reaction. This classification means they are documented but are generally not considered common effects experienced by most patients. Hypersensitivity to the drug is listed as an absolute contraindication.

---

Q: Is it normal to feel a mild burning sensation at the injection site for Даларгин-ДЕКО?

Official safety documentation lists localized effects, such as redness and soreness at the injection site, as a documented adverse reaction. This indicates that discomfort at the injection site is among the types of reactions that have been officially reported.

---

Q: Does Даларгин-ДЕКО cause extreme drowsiness or fatigue?

Official labeling lists dizziness and visual impairment as possible adverse reactions. However, the terms drowsiness or fatigue are not explicitly listed in the documented adverse reactions within the official product information.

---

Q: Can Даларгин-ДЕКО interact with common blood pressure medications?

While the official labeling does not explicitly detail specific drug-drug interaction warnings, it does note that the medicine is contraindicated in patients with pre-existing arterial hypotension, which means low blood pressure. All current medications should be reviewed with a healthcare provider, especially given the official cardiovascular precautions.

---

Q: If I am taking another peptide, can I also use Даларгин-ДЕКО?

The official interaction profile for this medicine does not describe specific interaction warnings, contraindications, or mandatory separation rules for co-administering it with other medicinal products, including other peptides. The consideration of co-administering any medications is subject to review by a medical professional.

---

Q: Is Даларгин-ДЕКО considered a painkiller or something else?

According to official product information, Даларгин-ДЕКО is classified as a Synthetic Peptide Drug and a Gastroprotective Agent. Its mechanism of action involves binding to delta- and mu-opioid receptors, which distinguishes its therapeutic purpose from general painkilling medications.

---

Q: Where is Даларгин-ДЕКО primarily approved for use?

The official prescribing information for Даларгин-ДЕКО is governed by the national regulatory authority in Russia (the Russian Medicines Register). This is the primary region where its authorized use is detailed.

---

Q: Is Даларгин-ДЕКО used long-term or short-term?

The official duration of treatment is strictly time-bound, classifying it as a short-term therapy. Courses are limited, lasting from a few days (such as 2 to 6 days for acute pancreatitis) up to several weeks (such as 3 to 4 weeks for peptic ulcer therapy).

---

Q: Does Даларгин-ДЕКО affect mental clarity or focus?

Official safety labeling lists dizziness and visual impairment as possible adverse reactions related to the medicine. The specific terms mental clarity or focus are not explicitly used in the official safety documentation when describing side effects.

Official Storage and Disposal Requirements

The official labeling for Даларгин-ДЕКО (Dalargin-DEKO) lyophilisate dictates specific mandatory conditions to maintain product stability and safety.

Storage Requirement	Condition
Temperature	Store between 2 C and 8 C (refrigerated).
Protection	Must be kept in the original package, protected from light.
Freezing	Do not freeze.

Stability and Handling

The product must be kept out of the reach of children. The prescribed shelf-life requires strict adherence to the 2 C to 8 C temperature range. Once the powder is reconstituted for injection, the resulting solution must be used immediately; it may be stored for a maximum of two hours at 2 C to 8 C before disposal. All unused or expired medicine must be discarded according to local pharmaceutical waste regulations.